Pub Date : 2026-02-09DOI: 10.1186/s12885-026-15715-x
Linjie Bian, Fanxuan Liu, Xuan Huang, Yige Peng, Yichong Fang, Lei Bi, Shaoli Song
{"title":"Noninvasive preoperative risk stratification of prostate cancer via a foundational model based deep learning with PSMA PET/CT.","authors":"Linjie Bian, Fanxuan Liu, Xuan Huang, Yige Peng, Yichong Fang, Lei Bi, Shaoli Song","doi":"10.1186/s12885-026-15715-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15715-x","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-09DOI: 10.1186/s12885-026-15701-3
Gao Li, Boxiao Li, Xin Zhang, Jianghua Jia
{"title":"Prognostic value of systemic immune-inflammation index and prognostic nutritional index in advanced prostate cancer: development and validation of a comprehensive nomogram.","authors":"Gao Li, Boxiao Li, Xin Zhang, Jianghua Jia","doi":"10.1186/s12885-026-15701-3","DOIUrl":"https://doi.org/10.1186/s12885-026-15701-3","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aberrant STAT3 activation and persistent expression of HPV16 E6E7 transcripts are pivotal drivers of cervical cancer (CaCx) progression. The present study was aimed to develop a Flow cytometry- based Florescence In situ hybridization (Flow-FISH) assay for simultaneous detection of STAT3 and HPV16 E6E7 transcripts at single-cell level. A set of 48 STAT3 multi locus probes and 18 HPV16 E6E7 probes were designed using Stellaris Probe Designer. Fluorescence microscopy using these probe sets generated discrete punctate signals for both individual and simultaneous hybridizations, enabling accurate transcript identification. Flow-cytometry analysis showed quantifiable STAT3 expression across CaCx cell lines, namely HeLa, SiHa and C33a. However, HPV16 E6E7 probes showed non-specific binding, which was addressed by redesigning the probes with increased stringency. The specificity of both probe sets was then evaluated through extensive sequence alignment against all known STAT3 transcript variants (n = 27) and 98 HPV16 isolates. The redesigned phase 2 HPV16 E6E7 probes were subsequently tested in cell lines, demonstrating robust detection in HPV16-positive SiHa and CaSki cells and complete absence of signal in HPV-negative controls (C33a, MSB1, SF21) or HPV18-positive HeLa cells. Dual-color flow cytometry enabled simultaneous quantification of STAT3 and HPV16 E6E7 transcripts in both cell lines and patient's exfoliated samples. Increased dual-positive fractions across LSIL, HSIL, and SCC samples were detected that corresponded with progressive viral oncogene activity and STAT3 co-activation. Overall, the optimized probe-based Flow-FISH assay provided a sensitive, specific, and high-throughput method for transcript-level diagnostics, with potential utility for stratifying cervical lesions.
{"title":"Development of a novel multi-locus Flow-FISH based assay for detection of progressive cervical precancer lesions.","authors":"Arun Chhokar, Udit Joshi, Chetkar Chandra Keshavam, Bindiya Gupta, Madeeha Mudassir, Divya Janjua, Apoorva Chaudhary, Tanya Tripathi, Joni Yadav, Nikita Aggarwal, Vinita Kumar Jaggi, Alok Chandra Bharti","doi":"10.1186/s12885-026-15664-5","DOIUrl":"https://doi.org/10.1186/s12885-026-15664-5","url":null,"abstract":"<p><p>Aberrant STAT3 activation and persistent expression of HPV16 E6E7 transcripts are pivotal drivers of cervical cancer (CaCx) progression. The present study was aimed to develop a Flow cytometry- based Florescence In situ hybridization (Flow-FISH) assay for simultaneous detection of STAT3 and HPV16 E6E7 transcripts at single-cell level. A set of 48 STAT3 multi locus probes and 18 HPV16 E6E7 probes were designed using Stellaris Probe Designer. Fluorescence microscopy using these probe sets generated discrete punctate signals for both individual and simultaneous hybridizations, enabling accurate transcript identification. Flow-cytometry analysis showed quantifiable STAT3 expression across CaCx cell lines, namely HeLa, SiHa and C33a. However, HPV16 E6E7 probes showed non-specific binding, which was addressed by redesigning the probes with increased stringency. The specificity of both probe sets was then evaluated through extensive sequence alignment against all known STAT3 transcript variants (n = 27) and 98 HPV16 isolates. The redesigned phase 2 HPV16 E6E7 probes were subsequently tested in cell lines, demonstrating robust detection in HPV16-positive SiHa and CaSki cells and complete absence of signal in HPV-negative controls (C33a, MSB1, SF21) or HPV18-positive HeLa cells. Dual-color flow cytometry enabled simultaneous quantification of STAT3 and HPV16 E6E7 transcripts in both cell lines and patient's exfoliated samples. Increased dual-positive fractions across LSIL, HSIL, and SCC samples were detected that corresponded with progressive viral oncogene activity and STAT3 co-activation. Overall, the optimized probe-based Flow-FISH assay provided a sensitive, specific, and high-throughput method for transcript-level diagnostics, with potential utility for stratifying cervical lesions.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-09DOI: 10.1186/s12885-026-15666-3
Natalia Zeber-Lubecka, Konrad Bilski, Michalina Dąbrowska, Krzysztof Goryca, Joanna Ziemska-Legięcka, Jerzy Ostrowski, Jakub Dobruch, Ewa E Hennig
Background: Bladder cancer (BC) is significantly more prevalent in men than in women, yet female patients often experience higher recurrence rates and poorer prognosis.
Methods: Our study aimed to investigate sex-specific gene expression differences in early-stage BC using whole-transcriptome sequencing. A total of 51 patients diagnosed with low-grade Ta stage non-muscle-invasive bladder cancer were recruited. Paired tissue samples from tumor lesions and adjacent healthy bladder mucosa (BM) were analyzed to identify differentially expressed genes (DEGs).
Results: Among the top 100 most significant DEGs for each gender, overwhelmingly more upregulated in BC comparing with BM were in male than female tissues (90% vs. 19%). The most significantly altered expression in female BC tissues included MT-ND6, ARL4C, ASGR1, MYBL1, and SCAMP5, whereas in males, ONECUT2, SPEG, CTSE, GJB2, and SYNM. Notably, 753 DEGs were unique to female patients, while 3989 were specific to males, with 1633 shared between both sexes. Functional annotation revealed that female-unique DEGs were significantly enriched in immune-related pathways, including regulation of leukocyte activation and cell-cell adhesion, and lymphocyte differentiation. Whereas male-unique DEGs were predominantly associated with pathways related to cell cycle regulation, mitochondrial function, and androgen receptor signaling. Immune-related gene expression indicated that female-specific DEGs were involved in leukocyte activation and antigen receptor signaling, whereas male-specific DEGs were linked to B-cell activation and neutrophil-mediated immune responses. A two-factor interaction model identified S100A14 as the only protein-coding gene whose expression exhibited a significant sex-dependent pattern, with four additional genes (GJB2, DSC2, TM4SF and ALOX15B) showing a probable interaction effect.
Conclusions: These findings provide preliminary evidence supporting further investigation of sex-specific approaches to BC management.
{"title":"Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.","authors":"Natalia Zeber-Lubecka, Konrad Bilski, Michalina Dąbrowska, Krzysztof Goryca, Joanna Ziemska-Legięcka, Jerzy Ostrowski, Jakub Dobruch, Ewa E Hennig","doi":"10.1186/s12885-026-15666-3","DOIUrl":"https://doi.org/10.1186/s12885-026-15666-3","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BC) is significantly more prevalent in men than in women, yet female patients often experience higher recurrence rates and poorer prognosis.</p><p><strong>Methods: </strong>Our study aimed to investigate sex-specific gene expression differences in early-stage BC using whole-transcriptome sequencing. A total of 51 patients diagnosed with low-grade Ta stage non-muscle-invasive bladder cancer were recruited. Paired tissue samples from tumor lesions and adjacent healthy bladder mucosa (BM) were analyzed to identify differentially expressed genes (DEGs).</p><p><strong>Results: </strong>Among the top 100 most significant DEGs for each gender, overwhelmingly more upregulated in BC comparing with BM were in male than female tissues (90% vs. 19%). The most significantly altered expression in female BC tissues included MT-ND6, ARL4C, ASGR1, MYBL1, and SCAMP5, whereas in males, ONECUT2, SPEG, CTSE, GJB2, and SYNM. Notably, 753 DEGs were unique to female patients, while 3989 were specific to males, with 1633 shared between both sexes. Functional annotation revealed that female-unique DEGs were significantly enriched in immune-related pathways, including regulation of leukocyte activation and cell-cell adhesion, and lymphocyte differentiation. Whereas male-unique DEGs were predominantly associated with pathways related to cell cycle regulation, mitochondrial function, and androgen receptor signaling. Immune-related gene expression indicated that female-specific DEGs were involved in leukocyte activation and antigen receptor signaling, whereas male-specific DEGs were linked to B-cell activation and neutrophil-mediated immune responses. A two-factor interaction model identified S100A14 as the only protein-coding gene whose expression exhibited a significant sex-dependent pattern, with four additional genes (GJB2, DSC2, TM4SF and ALOX15B) showing a probable interaction effect.</p><p><strong>Conclusions: </strong>These findings provide preliminary evidence supporting further investigation of sex-specific approaches to BC management.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15660-9
Yuxin Wang, Miao Lu, Xu Su, Chunying Cui, Wei Zhang, Guoping Wang
{"title":"Trend analysis of liver cancer mortality in Chinese residents from 2002 to 2021.","authors":"Yuxin Wang, Miao Lu, Xu Su, Chunying Cui, Wei Zhang, Guoping Wang","doi":"10.1186/s12885-026-15660-9","DOIUrl":"https://doi.org/10.1186/s12885-026-15660-9","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15690-3
Yinan Han, Jiang Qian, Jinwei Cheng, Li Yan
{"title":"The role of surgery plus radiation versus surgery alone in the management for complicated orbital solitary fibrous tumor: a new insight on a rare disease.","authors":"Yinan Han, Jiang Qian, Jinwei Cheng, Li Yan","doi":"10.1186/s12885-026-15690-3","DOIUrl":"https://doi.org/10.1186/s12885-026-15690-3","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15696-x
Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul
<p><strong>Aim: </strong>This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.</p><p><strong>Materials and methods: </strong>In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled. Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group. The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy. N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment. Between-group baseline characteristics were compared using the independent samples t-test for continuous variables. Within-group changes from baseline to 3 months were analyzed with paired t-tests. Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests. To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed. Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.</p><p><strong>Results: </strong>In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated. In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367 [95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p < 0.001). At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133 [95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001). Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.</p><p><strong>Conclusion: </strong>In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy. The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients. These hypothesis-generating findi
目的：本研究旨在通过超声心动图方法评估新诊断的乳腺癌合并2型糖尿病患者在二甲双胍的基础上同时接受达格列净治疗的阿霉素诱导的心脏毒性风险，并探讨达格列净的潜在心脏保护作用。材料与方法：本前瞻性观察研究共纳入60例新诊断的乳腺癌合并2型糖尿病患者。30例接受二甲双胍治疗的患者，在阿霉素治疗期间，在二甲双胍的基础上再接受达格列净治疗，构成达格列净组。非达格列净组包括30名患者，他们在继续使用二甲双胍的同时，在阿霉素治疗的同时开始使用另一种口服降糖药（不包括达格列净）。在基线和治疗第3个月测量n端前b型利钠肽（NT-proBNP）、左心室射血分数（LVEF）和左心室总纵向应变（LVGLS）。采用独立样本t检验对连续变量进行组间基线特征比较。用配对t检验分析从基线到3个月的组内变化。组间比较3个月的结果和变化（ΔLVEF， ΔLVGLS， ΔNT-proBNP）也采用独立样本t检验。为评价达格列净对LVGLS的独立影响，采用多变量线性回归分析。模型拟合报告采用调整后的R²、f统计量和95%置信区间。结果：在非达格列净组中，LVEF和NT-proBNP水平在基线和治疗后无显著差异；然而，LVGLS值明显恶化。相比而言，达格列净组在治疗3个月后LVEF （- 2.000 [95% CI - 2.392, - 1.608]）和LVGLS （+ 1.367 [95% CI + 1.159, + 1.574]）显著增加，NT-proBNP水平显著降低（+ 64.933 [95% CI + 57.902, + 71.964]） (p结论：达格列净与阿霉素治疗期间LVGLS和NT-proBNP的短期替代变化更有利相关。在LVEF、LVGLS和NT-proBNP参数中观察到的有利变化表明，达格列净可能被认为是一种潜在的心脏保护剂，可纳入糖尿病患者化疗相关心脏毒性的预防策略。这些产生假设的发现需要在更大规模的随机试验中得到证实，这些试验为临床终点提供了更长的随访时间。临床试验注册：不适用。
{"title":"Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.","authors":"Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul","doi":"10.1186/s12885-026-15696-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15696-x","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.</p><p><strong>Materials and methods: </strong>In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled. Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group. The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy. N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment. Between-group baseline characteristics were compared using the independent samples t-test for continuous variables. Within-group changes from baseline to 3 months were analyzed with paired t-tests. Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests. To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed. Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.</p><p><strong>Results: </strong>In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated. In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367 [95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p < 0.001). At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133 [95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001). Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.</p><p><strong>Conclusion: </strong>In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy. The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients. These hypothesis-generating findi","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15707-x
Jibril Bashir Adem, Abebe Megerso Adilo, Haji Aman Deybasso, Muhammed Kabeto, Anas Ali Alhur, Tewodros Desalegn Nebi, Gadisa Dejene, Mengesha Akale Tekle, Jemal Reshad Tarie, Mifta Dellil Hamid, Melik Tiba, Abashamo Lencho
{"title":"Lived experience and attitudes of esophageal cancer patients toward stenting-based care at Asella referral hospital: a qualitative exploration from a resource-limited setting in South-Eastern Ethiopia.","authors":"Jibril Bashir Adem, Abebe Megerso Adilo, Haji Aman Deybasso, Muhammed Kabeto, Anas Ali Alhur, Tewodros Desalegn Nebi, Gadisa Dejene, Mengesha Akale Tekle, Jemal Reshad Tarie, Mifta Dellil Hamid, Melik Tiba, Abashamo Lencho","doi":"10.1186/s12885-026-15707-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15707-x","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s12885-026-15632-z
Li Zhang, Fan Sun, Xiaorui Wang, Weipeng Zhao, Yongsheng Jia, Haotian Wang, Yuqi Han, Zhongsheng Tong
{"title":"Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.","authors":"Li Zhang, Fan Sun, Xiaorui Wang, Weipeng Zhao, Yongsheng Jia, Haotian Wang, Yuqi Han, Zhongsheng Tong","doi":"10.1186/s12885-026-15632-z","DOIUrl":"https://doi.org/10.1186/s12885-026-15632-z","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号